Lung cancer mutations and use of targeted agents in Hispanics - PubMed (original) (raw)

Review

Lung cancer mutations and use of targeted agents in Hispanics

W Douglas Cress et al. Rev Recent Clin Trials. 2014.

Abstract

Hispanic/Latinos (H/L) are expected to grow to over 24% of the USA population by 2050 and lung cancer is the number one cause of cancer death among H/L men. Due to the information that is becoming available via genetic testing, lung cancer molecular profiling is allowing for increasing application of personalized lung cancer therapies. However, to benefit the most people, development of these therapies and genetic tests must include research on as many racial and ethnic groups as possible. The purpose of this review is to bring attention to the fact that the mutations driving lung cancer in H/Ls differ in frequency and nature relative to the non-Hispanic White (WNH) majority that dominate current databases and participate in clinical trials that test new therapies. Clinical trials using new agents targeting genetic alterations (driver mutations) in lung cancer have demonstrated significant improvements in patient outcomes (for example, gefitinib, erlotinib or crizotinib for lung adenocarcinomas harboring EGFR mutations or EML4-ALK fusions, respectively). The nature and frequencies of some lung cancer driver mutations have been shown to be considerably different among racial and ethnic groups. This is particularly true for H/Ls. For example, several reports suggest a dramatic shift in the mutation pattern from predominantly KRAS in a WNH population to predominantly EGFR in multiple H/L populations. However, these studies are limited, and the effects of racial and ethnic differences on the incidence of mutations in lung cancer remain incompletely understood. This review serves as a call to address this problem.

PubMed Disclaimer

Conflict of interest statement

CONFLICT OF INTEREST

The authors confirm that this article content has no conflict of interest.

Similar articles

Cited by

References

    1. American Cancer Society. Cancer Facts & Figures for Hispanics/Latinos 2012–2014. Atlanta, GA: American Cancer Society; 2012.
    1. Pao W, Girard N. New driver mutations in non-small-cell lung cancer. Lancet Oncol. 2011;12(2):175–80. - PubMed
    1. Luo SY, Lam DC. Oncogenic driver mutations in lung cancer. Transl Resp Med. 2013;1(6):2–8. - PMC - PubMed
    1. Patel MI, Schupp CW, Gomez SL, Chang ET, Wakelee HA. How do social factors explain outcomes in non-small-cell lung cancer among Hispanics in California? Explaining the Hispanic paradox. J Clin Oncol. 2013;31(28):3572–8. - PMC - PubMed
    1. Pleasance ED, Stephens PJ, O’Meara S, et al. A small-cell lung cancer genome with complex signatures of tobacco exposure. Nature. 2010;463(7278):184–90. - PMC - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources